Growth Metrics

Gilead Sciences (GILD) Total Debt Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 12.60%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 5.23%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -5.51%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 40.96%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -0.10%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -11.13%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 3.78%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -10.56%
10 Gsk 88.34 Bn 83.66 Bn - 8.30%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -11.13%
Dec 31, 2025 -6.65%
Sep 30, 2025 7.28%
Jun 30, 2025 6.84%
Mar 31, 2025 -0.96%
Dec 31, 2024 6.90%
Sep 30, 2024 -6.94%
Jun 30, 2024 -7.51%
Mar 31, 2024 -0.18%
Dec 31, 2023 -0.96%
Sep 30, 2023 -0.96%
Jun 30, 2023 -3.70%
Mar 31, 2023 -3.70%
Dec 31, 2022 -5.49%
Sep 30, 2022 -8.90%
Jun 30, 2022 -13.12%
Mar 31, 2022 -13.12%
Dec 31, 2021 -14.99%
Sep 30, 2021 -5.48%
Jun 30, 2021 25.20%
Mar 31, 2021 25.19%
Dec 31, 2020 27.69%
Sep 30, 2020 19.12%
Jun 30, 2020 -7.59%
Mar 31, 2020 -9.33%
Dec 31, 2019 -9.99%
Sep 30, 2019 -9.99%
Jun 30, 2019 -10.24%
Mar 31, 2019 -8.52%
Dec 31, 2018 -18.54%
Sep 30, 2018 -6.65%
Jun 30, 2018 10.51%
Mar 31, 2018 10.38%
Dec 31, 2017 27.31%
Sep 30, 2017 8.09%
Jun 30, 2017 18.84%
Mar 31, 2017 15.33%
Dec 31, 2016 19.46%
Sep 30, 2016 21.80%
Jun 30, 2016 80.28%
Mar 31, 2016 84.60%
Dec 31, 2015 77.81%
Sep 30, 2015 136.18%
Jun 30, 2015 29.14%
Mar 31, 2015 26.10%
Dec 31, 2014 86.92%
Sep 30, 2014 28.67%
Jun 30, 2014 29.53%
Mar 31, 2014 22.58%
Dec 31, 2013 -19.31%
Sep 30, 2013 -16.62%
Jun 30, 2013 -19.36%
Mar 31, 2013 -15.18%
Dec 31, 2012 8.11%
Sep 30, 2012 125.29%
Jun 30, 2012 134.62%
Mar 31, 2012 109.38%
Dec 31, 2011 118.29%
Sep 30, 2011 515.66%
Mar 31, 2011 63,433.06%
Dec 31, 2010 62,275.48%
Sep 30, 2010 207.56%